Research Overview: Ziten
Ziten 20 mg is a pharmaceutical-grade teneligliptin formulation manufactured by Glenmark Pharmaceuticals Ltd. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor extensively studied in metabolic research applications. This compound represents a third-generation DPP-4 inhibitor with unique pharmacological properties that distinguish it from earlier generations in this therapeutic class. Researchers at Stroid UK Shop utilize pharmaceutical preparations like Ziten for investigating incretin hormone pathways and glucose homeostasis mechanisms in controlled laboratory environments.
Research Applications
Scientists investigate teneligliptin preparations for their selective DPP-4 enzyme inhibition properties in cell culture and tissue studies. The compound demonstrates prolonged binding kinetics to the DPP-4 active site, making it valuable for time-course experiments examining incretin hormone stability. Research teams study how DPP-4 inhibition affects glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) degradation pathways. Metabolic researchers examining selective androgen receptor modulators often compare insulin sensitivity effects with DPP-4 inhibitors in parallel studies. Additionally, laboratories investigating peptide hormones frequently examine teneligliptin’s impact on incretin processing. The compound’s oral bioavailability and tissue distribution characteristics make it suitable for pharmacokinetic research protocols. Studies examine its effects on hepatic glucose production, pancreatic beta-cell function, and alpha-cell glucagon secretion in experimental models. Research teams investigating diabetes pathophysiology utilize teneligliptin preparations to examine the incretin system’s role in postprandial glucose regulation. Some investigations focus on the compound’s potential cardiovascular and renal effects observed in clinical studies. Researchers studying various pharmaceutical compounds often incorporate DPP-4 inhibitors as reference standards for metabolic pathway analysis.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Teneligliptin 20 mg |
| Manufacturer | Glenmark Pharmaceuticals Ltd. |
| Form | Oral tablets |
| CAS Number | Verify with supplier |
| Molecular Formula | Verify with supplier |
| Storage | Room temperature, dry conditions |
| Shelf Life | As per manufacturer specifications |
| Quality Control | Pharmaceutical manufacturing standards |
Research Compliance
Ziten 20 mg tablets are supplied strictly for in-vitro research purposes and laboratory investigations. This pharmaceutical preparation is not intended for human consumption, clinical use, or therapeutic applications. Researchers must handle this compound according to institutional safety protocols and applicable regulations governing laboratory chemicals. Storage should follow manufacturer guidelines with appropriate temperature and humidity controls. All research applications must comply with local laboratory licensing requirements and institutional review board approvals where applicable.
